tiprankstipranks
BioMarin Pharmaceutical (GB:0HNC)
LSE:0HNC
UK Market
0HNC
BioMarin Pharmaceutical
RESEARCH TOOLSreports

BioMarin Pharmaceutical (0HNC) Share Forecast & Price Target

2 Followers
See the Price Targets and Ratings of:

0HNC Analyst Ratings

Strong Buy
21Ratings
Strong Buy
16 Buy
5 Hold
0 Sell
Based on 21 analysts giving stock ratings to
BioMarin
Pharmaceutical
in the past 3 months
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers​ in the past 3 months

0HNC Stock 12 Month Forecast

Average Price Target

$92.70
▲(40.41% Upside)
Based on 21 Wall Street analysts offering 12 month price targets for BioMarin Pharmaceutical in the last 3 months. The average price target is $92.70 with a high forecast of $124.00 and a low forecast of $60.00. The average price target represents a 40.41% change from the last price of $66.02.
{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"51":"$51","88":"$88","125":"$125","69.5":"$69.5","106.5":"$106.5"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":124,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$124.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":92.7,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$92.70</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":60,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$60.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[51,69.5,88,106.5,125],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Dec<br/>2025","6":"Mar<br/>2026","9":"Jun<br/>2026","12":"Sep<br/>2026","25":"Sep<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,66.02,70.47999999999999,74.94,79.39999999999999,83.86,88.32,92.78,97.24,101.69999999999999,106.16,110.62,115.08,119.53999999999999,{"y":124,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,66.02,68.07230769230769,70.12461538461538,72.17692307692307,74.22923076923077,76.28153846153846,78.33384615384615,80.38615384615385,82.43846153846154,84.49076923076923,86.54307692307692,88.59538461538462,90.64769230769231,{"y":92.7,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,66.02,65.55692307692307,65.09384615384614,64.63076923076923,64.1676923076923,63.70461538461538,63.24153846153846,62.778461538461535,62.315384615384616,61.85230769230769,61.38923076923077,60.926153846153845,60.463076923076926,{"y":60,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":58.039,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 34,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":54.546,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 46,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 10, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":52.84,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 27,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":55.272,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 25,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 10, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":59.39,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":58.05,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 25,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 11, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":59.902,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 28,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":57.081,"date":1775001600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 26,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":54.01,"date":1777593600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 38,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 10, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":55.38,"date":1780272000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 32,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 10, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":57.78,"date":1782864000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 32,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 13, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":59.59,"date":1785542400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 26,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 14, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":66.02,"date":1788220800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 28,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 14, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}
Highest Price Target$124.00Average Price Target$92.70Lowest Price Target$60.00
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts​

Detailed List of Analyst Forecasts​
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
Piper Sandler Analyst forecast on GB:0HNC
Allison Bratzel
Piper Sandler
Piper Sandler
$88→$90
Buy
36.32%
Upside
Reiterated
09/01/26
Analysts Conflicted on These Healthcare Names: Axsome Therapeutics (NASDAQ: AXSM), BioMarin Pharmaceutical (NASDAQ: BMRN) and Envista Holdings (NYSE: NVST)
Morgan Stanley Analyst forecast on GB:0HNC
Sean Laaman
Morgan Stanley
Morgan Stanley
$124
Buy
87.82%
Upside
Assigned
09/01/26
Morgan Stanley Keeps Their Buy Rating on BioMarin Pharmaceutical (BMRN)
H.C. Wainwright Analyst forecast on GB:0HNC
Mitchell Kapoor
H.C. Wainwright
H.C. Wainwright
$59→$60
Hold
-9.12%
Downside
Reiterated
09/01/26
BioMarin Kept at Hold as YUVIWEL Royalties Lift DCF and Price Target Rises from $59 to $60 Amid VOXZOGO Headwinds
Cantor Fitzgerald Analyst forecast on GB:0HNC
Olivia Brayer
Cantor Fitzgerald
Cantor Fitzgerald
$85→$86
Buy
30.26%
Upside
Reiterated
09/01/26
Analysts Offer Insights on Healthcare Companies: IDEAYA Biosciences (NASDAQ: IDYA), BioMarin Pharmaceutical (NASDAQ: BMRN) and Karyopharm Therapeutics (NASDAQ: KPTI)
William Blair Analyst forecast on GB:0HNC
Sami Corwin
William Blair
William Blair
―
Hold
―
Reiterated
08/31/26
Analysts Have Conflicting Sentiments on These Healthcare Companies: BioMarin Pharmaceutical (NASDAQ: BMRN) and BridgeBio Pharma (NASDAQ: BBIO)
Stifel Nicolaus Analyst forecast on GB:0HNC
Paul Matteis
Stifel Nicolaus
Stifel Nicolaus
$70
Hold
6.03%
Upside
Reiterated
08/31/26
Analysts Conflicted on These Healthcare Names: Arrowhead Pharmaceuticals (NASDAQ: ARWR), BioMarin Pharmaceutical (NASDAQ: BMRN) and Ionis Pharmaceuticals (NASDAQ: IONS)
Canaccord Genuity Analyst forecast on GB:0HNC
Whitney Ijem
Canaccord Genuity
Canaccord Genuity
$114
Buy
72.67%
Upside
Reiterated
08/31/26
BioMarin Settlement with Ascendis Clears Legal Overhang; Analyst Reaffirms Buy Rating and Maintains $114 Price Target
Jefferies Analyst forecast on GB:0HNC
Akash Tewari
Jefferies
Jefferies
$104→$105
Buy
59.04%
Upside
Reiterated
08/31/26
Analyst Sees BioMarin Undervalued After Ascendis Settlement, Modestly Raising Price Target to $105
Wells Fargo Analyst forecast on GB:0HNC
Mohit Bansal
Wells Fargo
Wells Fargo
$80
Buy
21.18%
Upside
Reiterated
08/31/26
BioMarin Pharmaceutical (BMRN) Receives a Buy from Wells Fargo
Goldman Sachs Analyst forecast on GB:0HNC
Salveen Richter
Goldman Sachs
Goldman Sachs
$70
Hold
6.03%
Upside
Reiterated
08/31/26
Balanced Upside and Execution Risks Lead Richter to Maintain Hold on BioMarin After ASND Settlement and Voxzogo Expansion Plans
TD Cowen Analyst forecast on GB:0HNC
Phil Nadeau
TD Cowen
TD Cowen
$120
Buy
81.76%
Upside
Reiterated
08/20/26
Analysts Offer Insights on Healthcare Companies: Avita Medical (NASDAQ: RCEL) and BioMarin Pharmaceutical (NASDAQ: BMRN)
BMO Capital Analyst forecast on GB:0HNC
Unknown Analyst
BMO Capital
Not Ranked
BMO Capital
$98
Buy
48.44%
Upside
Initiated
08/18/26
BioMarin initiated with an Outperform at BMO CapitalBioMarin initiated with an Outperform at BMO Capital
Bank of America Securities Analyst forecast on GB:0HNC
Jason Gerberry
Bank of America Securities
Bank of America Securities
$86
Buy
30.26%
Upside
Reiterated
08/18/26
Analysts' Top Healthcare Picks: BioMarin Pharmaceutical (BMRN), Immatics (IMTX)
Wedbush Analyst forecast on GB:0HNC
Yun Zhong
Wedbush
Wedbush
$94
Buy
42.38%
Upside
Reiterated
08/18/26
Analysts' Top Healthcare Picks: Amylyx Pharmaceuticals Inc (AMLX), BioMarin Pharmaceutical (BMRN)
Barclays Analyst forecast on GB:0HNC
Eliana Merle
Barclays
Barclays
$105→$111
Buy
68.13%
Upside
Reiterated
08/17/26
Analysts Offer Insights on Healthcare Companies: Phathom Pharmaceuticals (NASDAQ: PHAT) and BioMarin Pharmaceutical (NASDAQ: BMRN)
Analyst Type
Any
Any
Human Analysts
Ranks
Any
Any
Analyst Rating
Any
Any
Upside/ Downside
Any
Any
Action
Any
Any
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
Piper Sandler Analyst forecast on GB:0HNC
Allison Bratzel
Piper Sandler
Piper Sandler
$88→$90
Buy
36.32%
Upside
Reiterated
09/01/26
Analysts Conflicted on These Healthcare Names: Axsome Therapeutics (NASDAQ: AXSM), BioMarin Pharmaceutical (NASDAQ: BMRN) and Envista Holdings (NYSE: NVST)
Morgan Stanley Analyst forecast on GB:0HNC
Sean Laaman
Morgan Stanley
Morgan Stanley
$124
Buy
87.82%
Upside
Assigned
09/01/26
Morgan Stanley Keeps Their Buy Rating on BioMarin Pharmaceutical (BMRN)
H.C. Wainwright Analyst forecast on GB:0HNC
Mitchell Kapoor
H.C. Wainwright
H.C. Wainwright
$59→$60
Hold
-9.12%
Downside
Reiterated
09/01/26
BioMarin Kept at Hold as YUVIWEL Royalties Lift DCF and Price Target Rises from $59 to $60 Amid VOXZOGO Headwinds
Cantor Fitzgerald Analyst forecast on GB:0HNC
Olivia Brayer
Cantor Fitzgerald
Cantor Fitzgerald
$85→$86
Buy
30.26%
Upside
Reiterated
09/01/26
Analysts Offer Insights on Healthcare Companies: IDEAYA Biosciences (NASDAQ: IDYA), BioMarin Pharmaceutical (NASDAQ: BMRN) and Karyopharm Therapeutics (NASDAQ: KPTI)
William Blair Analyst forecast on GB:0HNC
Sami Corwin
William Blair
William Blair
―
Hold
―
Reiterated
08/31/26
Analysts Have Conflicting Sentiments on These Healthcare Companies: BioMarin Pharmaceutical (NASDAQ: BMRN) and BridgeBio Pharma (NASDAQ: BBIO)
Stifel Nicolaus Analyst forecast on GB:0HNC
Paul Matteis
Stifel Nicolaus
Stifel Nicolaus
$70
Hold
6.03%
Upside
Reiterated
08/31/26
Analysts Conflicted on These Healthcare Names: Arrowhead Pharmaceuticals (NASDAQ: ARWR), BioMarin Pharmaceutical (NASDAQ: BMRN) and Ionis Pharmaceuticals (NASDAQ: IONS)
Canaccord Genuity Analyst forecast on GB:0HNC
Whitney Ijem
Canaccord Genuity
Canaccord Genuity
$114
Buy
72.67%
Upside
Reiterated
08/31/26
BioMarin Settlement with Ascendis Clears Legal Overhang; Analyst Reaffirms Buy Rating and Maintains $114 Price Target
Jefferies Analyst forecast on GB:0HNC
Akash Tewari
Jefferies
Jefferies
$104→$105
Buy
59.04%
Upside
Reiterated
08/31/26
Analyst Sees BioMarin Undervalued After Ascendis Settlement, Modestly Raising Price Target to $105
Wells Fargo Analyst forecast on GB:0HNC
Mohit Bansal
Wells Fargo
Wells Fargo
$80
Buy
21.18%
Upside
Reiterated
08/31/26
BioMarin Pharmaceutical (BMRN) Receives a Buy from Wells Fargo
Goldman Sachs Analyst forecast on GB:0HNC
Salveen Richter
Goldman Sachs
Goldman Sachs
$70
Hold
6.03%
Upside
Reiterated
08/31/26
Balanced Upside and Execution Risks Lead Richter to Maintain Hold on BioMarin After ASND Settlement and Voxzogo Expansion Plans
TD Cowen Analyst forecast on GB:0HNC
Phil Nadeau
TD Cowen
TD Cowen
$120
Buy
81.76%
Upside
Reiterated
08/20/26
Analysts Offer Insights on Healthcare Companies: Avita Medical (NASDAQ: RCEL) and BioMarin Pharmaceutical (NASDAQ: BMRN)
BMO Capital Analyst forecast on GB:0HNC
Unknown Analyst
BMO Capital
Not Ranked
BMO Capital
$98
Buy
48.44%
Upside
Initiated
08/18/26
BioMarin initiated with an Outperform at BMO CapitalBioMarin initiated with an Outperform at BMO Capital
Bank of America Securities Analyst forecast on GB:0HNC
Jason Gerberry
Bank of America Securities
Bank of America Securities
$86
Buy
30.26%
Upside
Reiterated
08/18/26
Analysts' Top Healthcare Picks: BioMarin Pharmaceutical (BMRN), Immatics (IMTX)
Wedbush Analyst forecast on GB:0HNC
Yun Zhong
Wedbush
Wedbush
$94
Buy
42.38%
Upside
Reiterated
08/18/26
Analysts' Top Healthcare Picks: Amylyx Pharmaceuticals Inc (AMLX), BioMarin Pharmaceutical (BMRN)
Barclays Analyst forecast on GB:0HNC
Eliana Merle
Barclays
Barclays
$105→$111
Buy
68.13%
Upside
Reiterated
08/17/26
Analysts Offer Insights on Healthcare Companies: Phathom Pharmaceuticals (NASDAQ: PHAT) and BioMarin Pharmaceutical (NASDAQ: BMRN)
Stocks with the Highest Top Analyst Consensus in the Healthcare Sector
ODTXOdyssey Therapeutics, Inc.
BTSGBrightSpring Health Services, Inc.
GPCRStructure Therapeutics, Inc. Sponsored ADR
AMLXAmylyx Pharmaceuticals Inc
IMMXImmix Biopharma
Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering BioMarin Pharmaceutical

3 Months
Christopher RaymondRaymond James
Success Rate
16/36 ratings generated profit
44%
Average Return
-0.04%
Copying Christopher Raymond's trades and holding each position for 3 Months would result in 44.44% of your transactions generating a profit, with an average return of -0.04% per trade.
1 Year
Cory KasimovEvercore ISI
Success Rate
22/43 ratings generated profit
51%
Average Return
-2.55%
Copying Cory Kasimov's trades and holding each position for 1 Year would result in 51.16% of your transactions generating a profit, with an average return of -2.55% per trade.
2 Years
Phil NadeauTD Cowen
Success Rate
16/26 ratings generated profit
62%
Average Return
-0.51%
Copying Phil Nadeau's trades and holding each position for 2 Years would result in 61.54% of your transactions generating a profit, with an average return of -0.51% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

0HNC Analyst Recommendation Trends

Rating
May 26
Jun 26
Jul 26
Aug 26
Sep 26
Strong Buy
27
26
25
16
16
Buy
11
6
7
10
12
Hold
10
10
13
14
14
Sell
0
0
0
0
0
Strong Sell
0
0
0
0
0
total
48
42
45
40
42
In the current month, 0HNC has received 28 Buy Ratings, 14 Hold Ratings, and 0 Sell Ratings. 0HNC average Analyst price target in the past 3 months is 92.70.
Each month's total comprises the sum of three months' worth of ratings.

0HNC Financial Forecast

0HNC Earnings Forecast

Next quarter’s earnings estimate for 0HNC is $1.34 with a range of $1.22 to $1.44. The previous quarter’s EPS was $1.20. 0HNC beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 57.80% of the time in the same period. In the last calendar year 0HNC has Performed in-line its overall industry.
Next quarter’s earnings estimate for 0HNC is $1.34 with a range of $1.22 to $1.44. The previous quarter’s EPS was $1.20. 0HNC beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 57.80% of the time in the same period. In the last calendar year 0HNC has Performed in-line its overall industry.

0HNC Sales Forecast

Next quarter’s sales forecast for 0HNC is $1.03B with a range of $1.00B to $1.07B. The previous quarter’s sales results were $996.38M. 0HNC beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 50.04% of the time in the same period. In the last calendar year 0HNC has Performed in-line its overall industry.
Next quarter’s sales forecast for 0HNC is $1.03B with a range of $1.00B to $1.07B. The previous quarter’s sales results were $996.38M. 0HNC beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 50.04% of the time in the same period. In the last calendar year 0HNC has Performed in-line its overall industry.

0HNC Stock Forecast FAQ

What is GB:0HNC’s average 12-month price target, according to analysts?
Based on analyst ratings, BioMarin Pharmaceutical’s 12-month average price target is 92.70.
    What is GB:0HNC’s upside potential, based on the analysts’ average price target?
    BioMarin Pharmaceutical has 40.41% upside potential, based on the analysts’ average price target.
      Can I see which stocks the top-ranking analysts are rating?
      Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
        How can I follow the stock ratings of top Wall Street analysts?
        Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
          Is BioMarin Pharmaceutical a Buy, Sell or Hold?
          BioMarin Pharmaceutical has a consensus rating of Strong Buy, which is based on 16 buy ratings, 5 hold ratings and 0 sell ratings.
            What is BioMarin Pharmaceutical’s share price target?
            The average share price target for BioMarin Pharmaceutical is 92.70. This is based on 21 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
            The highest analyst share price target is $124.00 ,and the lowest forecast is $60.00. The average share price target represents 40.41% Increase from the current price of $66.02.
              What do analysts say about BioMarin Pharmaceutical?
              BioMarin Pharmaceutical’s analyst rating consensus is a Strong Buy. This is based on the ratings of 21 Wall Streets Analysts.
                How can I buy shares of BioMarin Pharmaceutical?
                To buy shares of GB:0HNC, you can open a brokerage account. See exclusive account opening deals on our Best Online Brokers page.